| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1115 | 2021 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 654* | 2021 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 317 | 2021 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10289), 2049, 2021 | 299 | 2021 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 219 | 2022 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 192 | 2022 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 76 | 2022 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10320), 143-151, 2022 | 45 | 2022 |
| Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials CAM Fulgenzi, B Scheiner, J Korolewicz, CV Stikas, A Gennari, ... JHEP Reports 5 (5), 100702, 2023 | 24 | 2023 |
| Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open … O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 401 (10387), 1499-1507, 2023 | 15 | 2023 |
| Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet Diabetes & Endocrinology 11 (12), 905-914, 2023 | 8 | 2023 |
| Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC):“Real world” experience DR Bakaloudi, R Talukder, GI Lin, D Makrakis, LN Diamantopoulos, ... Clinical genitourinary cancer 21 (5), 584-593, 2023 | 5 | 2023 |
| Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised … SN Faust, R Haynes, CE Jones, N Staplin, E Whittaker, T Jaki, E Juszczak, ... The Lancet Child & Adolescent Health 8 (3), 190-200, 2024 | 4 | 2024 |
| Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in … A D'Alessio, M Pai, D Spalding, RD Goldin, B Scheiner, J Korolewicz, ... Journal of Clinical Oncology 41 (16_suppl), 4129-4129, 2023 | 4 | 2023 |
| PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma P Fessas, B Scheiner, A D'Alessio, CA M Fulgenzi, J Korolewicz, C Ward, ... Future Oncology 19 (7), 499-507, 2023 | 4 | 2023 |
| Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma S Dharmapuri, U Özbek, H Jethra, T Jun, TU Marron, A Saeed, YH Huang, ... World journal of gastrointestinal oncology 15 (11), 1900, 2023 | 2 | 2023 |
| The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab A D’Alessio, C Fulgenzi, B Scheiner, J Korolewicz, J Cheon, N Nishida, ... Journal of Hepatology 78, S575, 2023 | 2 | 2023 |
| Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma GF Manfredi, C Celsa, C John, C Jones, N Acuti, B Scheiner, ... Journal of Hepatocellular Carcinoma, 1955-1971, 2023 | 1 | 2023 |
| Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study V Joerg, B Scheiner, CAM Fulgenzi, M Schönlein, L Kocheise, AW Lohse, ... Hepatology Communications 7 (11), e0302, 2023 | 1 | 2023 |
| Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients (pts) with advanced urothelial carcinoma (aUC):" Real world" experience. DR Bakaloudi, R Talukder, D Makrakis, N Agarwal, N Tripathi, A Bamias, ... Journal of Clinical Oncology 41 (6_suppl), 472-472, 2023 | 1 | 2023 |
